Pfizer – Page 5

Pfizer’s Subcutaneous PD-1 Inhibitor Sasanlimab Achieves Significant Efficacy in High-Risk Non-Muscle Invasive Bladder Cancer

7 months ago talkbio0Tagged BCG Vaccine, BCG-Naïve, Combined Modality Therapy, Event-Free Survival, Inhibitor, Invasive, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, PDCD1 gene, Pfizer, Sasanlimab, subcutaneous

Pfizer, Sasanlimab, Subcutaneous PD-1 inhibitor, Non-muscle invasive bladder cancer (NMIBC), BCG-naïve, Event-free survival (EFS), Combination therapy with BCG

Pfizer’s Sasanlimab Shows Promising Results in Phase 3 Trial for High-Risk Non-Muscle Invasive Bladder Cancer

7 months ago talkbio0Tagged BCG Vaccine, Blocker, Carcinoma of urinary bladder, invasive, Keytruda, Malignant neoplasm of urinary bladder, Non-Muscle, PDCD1 gene, Pfizer, Phase 3 trial, Sasanlimab

Pfizer, Sasanlimab, PD-1 Blocker, Bladder Cancer, Phase 3 Trial, Non-Muscle Invasive Bladder Cancer, BCG, Keytruda

FDA Mandates Guillain-Barré Syndrome Warning for Pfizer and GSK RSV Vaccines

8 months ago talkbio0Tagged Abrysvo, Arexvy, Cautionary Warning, Guillain-Barré syndrome, Pfizer, Respiratory syncytial virus, SmithKline Beecham, United States Food and Drug Administration, Vaccines

RSV vaccines, Guillain-Barré syndrome, FDA warning, Pfizer, GSK, Abrysvo, Arexvy

Pfizer and PostEra Expand AI-Driven Drug Discovery Partnership to Include Antibody-Drug Conjugates (ADCs)

8 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Aortic Valve Insufficiency, Chemistry, Pharmaceutical, Drug Discovery, Immunostimulating conjugate (antigen), Laboratory, Pfizer, Pfizer/, PostEra, Proton Platform, Small Molecule

AI-driven drug discovery, Antibody-Drug Conjugates (ADCs), Pfizer, PostEra, AI Lab, Proton platform, small molecule therapeutics, medicinal chemistry.

Pfizer Terminates Development of Sangamo’s Hemophilia A Gene Therapy, Returning Full Rights to Sangamo

8 months ago talkbio0Tagged Fitelparvovec, gene therapy, Giroctocogene, Hemophilia A, Pfizer, Phase 3 AFFINE Trial

Pfizer, Sangamo Therapeutics, Hemophilia A, Gene Therapy, Giroctocogene Fitelparvovec, Phase 3 AFFINE Trial

Pfizer Terminates Hemophilia A Gene Therapy Partnership with Sangamo, Citing Commercial Viability Concerns

8 months ago talkbio0Tagged commercial, gene therapy, Hemophilia A, partnership termination, Pfizer, Viable

Pfizer, Sangamo Therapeutics, Hemophilia A, Gene Therapy, Commercial Viability, Partnership Termination

BioNTech Resolves COVID-19 Vaccine Royalty Disputes with NIH and UPenn

8 months ago talkbio0Tagged Agreement, BioNTech, COVID19 (disease), Disputes, NIH Mouse, Pfizer, Royalty, settlement, UPenn, Vaccines

BioNTech, COVID-19 vaccine, royalty disputes, NIH, UPenn, Pfizer, settlement agreements

Pfizer Transfers Global Creative Duties to Publicis in Strategic Marketing Shift

8 months ago talkbio0Tagged Drug Industry, Pfizer, Publicis

Pfizer, Publicis, global creative duties, marketing strategy, pharmaceutical industry

Pfizer’s Breakthrough Hemophilia Drug Hympavzi Wins EU Approval

9 months ago talkbio0Tagged Approved, EU, Hemophilia A, Hemophilia B, HYMPAVZI, marstacimab, once-weekly, Pfizer, pre-filled auto-injector pen, Subcutaneous Treatment

Pfizer, Hympavzi, EU approval, hemophilia A, hemophilia B, marstacimab, once-weekly subcutaneous treatment, pre-filled auto-injector pen

Pfizer Expands Collaboration with Flagship Pioneering, Adding Ampersand Biomedicines and Montai Therapeutics

9 months ago talkbio0Tagged Ampersand, Biomedicines, Drug Development, Flagship, Montai, Non-Small Cell Lung Carcinoma, Obesity, Pfizer, Pioneering, strategic partnership

Pfizer, Flagship Pioneering, Ampersand Biomedicines, Montai Therapeutics, strategic partnership, drug development, obesity, non-small cell lung cancer